PRODUCT INFORMATION

Moexiprilat

Item No. 38047

CAS Registry No.: 103775-14-0
Formal Name: (3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
Synonym: RS 10029
MF: $C_{25}H_{30}N_2O_7$
FW: 470.5
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Moexiprilat is supplied as a solid. A stock solution may be made by dissolving the moexiprilat in the solvent of choice, which should be purged with an inert gas. Moexiprilat is soluble in methanol and DMSO.

Description

Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC_{50} = 2.1 nM) and an active metabolite of the prodrug moexipril (Item No. 21255).[1] It is formed from moexipril *in vivo* by side chain ester hydrolysis.[2] Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts.[3] It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.[4]

References

1. Edling, O., Bao, G., Feelisch, M., *et al.* Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. *J. Pharmacol. Exp. Ther.* **275(2)**, 854-863 (1995).
2. Cameron, R.T., Coleman, R.G., Day, J.P., *et al.* Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). *Biochem. Pharmacol.* **85(9)**, 1297-1305 (2013).
3. Grohé, C., Kahlert, S., Löbber, K., *et al.* Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth. *J. Hypertens.* **16(3)**, 377-384 (1998).
4. van Eickels, M., Schreckenberg, R., Doevendans, P.A., *et al.* The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats. *Eur. J. Heart Fail.* **7(7)**, 1079-1084 (2005).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM